These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. Chan HL, Wong VW, Hui AY, Tsang SW, Chan JL, Chan HY, Wong GL, Sung JJ. Antivir Ther; 2006; 11(4):465-71. PubMed ID: 16856620 [Abstract] [Full Text] [Related]
8. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Hepatology; 2002 Jul; 36(1):219-26. PubMed ID: 12085368 [Abstract] [Full Text] [Related]
16. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study. Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490 [Abstract] [Full Text] [Related]
17. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis. Viganò M, Colombo M, Aroldi A, Lunghi G, Manenti E, Ponticelli C, Lampertico P. Antivir Ther; 2005 Apr; 10(6):709-13. PubMed ID: 16218169 [Abstract] [Full Text] [Related]